A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma
Open Access
- 15 March 2002
- Vol. 94 (6), 1747-1752
- https://doi.org/10.1002/cncr.10407
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is a common cause of cancer death throughout the world. The majority of patients are not suitable for curative resection either because of the advanced stage of the disease at the time of presentation or because of underlying cirrhosis. Transcatheter intraarterial lipiodol chemoembolization (TACE) has been reported to be one of the most effective palliative measures for HCC. However, its severe side effects continue to make its use controversial. METHODS In the current study, the authors prospectively evaluated 197 sessions of TACE performed in 59 patients with HCC. RESULTS Acute hepatic decompensation occurred in 20% of the 197 sessions with 3% of cases being irreversible. Significant elevation of bilirubin was associated with the dosage of cisplatin used (P = 0.0001), basal bilirubin level (P = 0.0001), basal prothrombin time (P =0.004), basal aspartate aminotransferase (AST) level (P = 0.013), and stage of cirrhosis (P < 0.0001). Patients with irreversible hepatic decompensation were more likely to have higher pre‐TACE bilirubin levels (P = 0.009), more prolonged prothrombin time (P = 0.015), received a higher dose of cisplatin (P = 0.033), and more advanced cirrhosis (P < 0.0001). The majority of the other side effects were self‐limiting with the exception of one patient who died of liver and splenic abscesses. Approximately 36% of the patients achieved a tumor response, 39% achieved stable disease, and 29% developed progressive disease. CONCLUSIONS The results of the current study identified factors that appeared to predispose patients to irreversible hepatic decompensation after TACE. Despite the high percentage of patients who developed hepatic decompensation after TACE, irreversible damage occurred in only a minority. Cancer 2002;94:1747–52. © 2002 American Cancer Society. DOI 10.1002/cncr.10407Keywords
This publication has 21 references indexed in Scilit:
- Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experienceJournal of Hepatology, 2000
- Bacterial Infections Associated with Hepatic Arteriography and Transarterial Embolization for Hepatocellular Carcinoma: A Prospective StudyClinical Infectious Diseases, 1999
- Transcatheter Arterial Chemoembolization in Inoperable Hepatocellular Carcinoma: Four-year Follow-upJournal of Vascular and Interventional Radiology, 1996
- A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular CarcinomaThe New England Journal of Medicine, 1995
- Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trialsJournal of Hepatology, 1994
- Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patientsJournal of Hepatology, 1991
- Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma: Assessment by maximal removal rate of indocyanine greenJournal of Hepatology, 1988
- A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin spongeCancer, 1987
- Gallbladder infarction after hepatic artery embolizationAmerican Journal of Roentgenology, 1985
- Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liverCancer, 1983